At 12 weeks, more patients who took HUMIRA saw 20% improvement in their signs and symptoms of PsA, including joint pain and swelling, than those taking placebo.
Of patients evaluated for skin symptoms, the majority of those taking HUMIRA saw a 75% improvement in their skin symptoms at 24 weeks.
In the same study, patients taking HUMIRA showed a reduction in further joint damage, compared with patients taking placebo at week 24, and this effect was maintained at 48 weeks. Additionally, the % of patients who showed no further joint damage at week 24 was:
9 out of 10 who took HUMIRA showed no further joint damage (as measured by X-ray) vs 7 out of 10 who took placebo at 24 weeks.
Some patients saw improvements in joint and skin symptoms as soon as 2 weeks.†
*A placebo is a substance that has no physical effect. In a clinical study, it is given to one group of patients, while the drug being tested is given to another group. Then the results are compared.
†Results may take 24 weeks or longer. Individual results may vary.